RESUMO
Arsenic (As)-contaminated soil reduces soil quality and leads to soil degradation, and traditional remediation strategies are expensive or typically produce hazardous by-products that have negative impacts on ecosystems. Therefore, this investigation attempts to assess the impact of As-tolerant bacterial isolates via a bacterial Rhizobim nepotum strain (B1), a bacterial Glutamicibacter halophytocola strain (B2), and MgO-NPs (N) and their combinations on the arsenic content, biological activity, and growth characteristics of maize plants cultivated in highly As-contaminated soil (300 mg As Kg-1). The results indicated that the spectroscopic characterization of MgO-NPs contained functional groups (e.g., Mg-O, OH, and Si-O-Si) and possessed a large surface area. Under As stress, its addition boosted the growth of plants, biomass, and chlorophyll levels while decreasing As uptake. Co-inoculation of R. nepotum and G. halophytocola had the highest significant values for chlorophyll content, soil organic matter (SOM), microbial biomass (MBC), dehydrogenase activity (DHA), and total number of bacteria compared to other treatments, which played an essential role in increasing maize growth. The addition of R. nepotum and G. halophytocola alone or in combination with MgO-NPs significantly decreased As uptake and increased the biological activity and growth characteristics of maize plants cultivated in highly arsenic-contaminated soil. Considering the results of this investigation, the combination of G. halophytocola with MgO-NPs can be used as a nanobioremediation strategy for remediating severely arsenic-contaminated soil and also improving the biological activity and growth parameters of maize plants.
RESUMO
BACKGROUND: Allergic diseases are immunological exaggerations with symptoms that may interfere with life quality. Bilastine, a novel oral second-generation H-1 antihistamine, is highly selective to H-1 receptors and has anti inflammatory properties. The present evidence regarding the drug efficacy is inconsistent. OBJECTIVES: We aimed to evaluate the efficacy and safety of bilastine compared with the placebo and other active antihistamines in patients who complained either from AR or chronic urticaria. METHODS: We systematically searched the Medline, Scopus, Web of Science, and Cochrane databases for randomized controlled trials (RCTs) evaluating bilastine effects on symptomatic hyper histaminic allergic conditions. We collected data on total symptoms scores (TSS), total nasal symptom scores (TNSS), discomfort associated with these allergic conditions measured by visual analog score (VAS), and quality of life (QOL) for AR and urticaria. Other outcomes such as clinical global impression and safety profiles were reported as well. We pooled the studies in a random effect model using RevMan 5.4 software. RESULTS: We included 9 RCTs comprising 3801 participants. The meta-analysis revealed that bilastine was superior to placebo, improving TSS, TNSS, VAS, and QOL in AR or chronic urticaria participants. Moreover, the bilastine was comparable to active antihistamines such as cetirizine, fexofenadine, and loratadine regarding mentioned outcomes. In addition, the novel drug was safe and tolerable with no difference in the incidence of adverse events with a placebo. CONCLUSIONS: Bilastine safely improved TSS in hyper histaminic allergic conditions involving nasal symptoms in AR. It decreases the discomfort associated with the disease resulting in improving the QOL of the participants.
